Use of the PATH Alliance database to measure adherence to IDSA guidelines for the therapy of candidemia
- PMID: 17899230
- DOI: 10.1007/s10096-007-0383-4
Use of the PATH Alliance database to measure adherence to IDSA guidelines for the therapy of candidemia
Abstract
Candidemia is an increasing complication of the care of complex patients. Adherence to Infectious Diseases Society of America (IDSA) guidelines for the treatment of candidemia was investigated to assess the impact of compliance on outcomes of therapy. Data on the epidemiology, diagnosis, and treatment of patients with invasive fungal infections (IFIs) was extracted from the PATH Alliance registry, a prospective, multicenter, observational database of invasive fungal infections. Patients with proven candidemia were evaluated for adherence to the IDSA guidelines in terms of choice, dosage, and duration of antifungal therapy. Removal of central venous catheters and time to treatment initiation were assessed. Four-week survival data were compared. Of the 418 patients with candidemia who were included in the study, 361 patients with the necessary data sets were identified, of whom 262 (72.6%) were treated within the IDSA guidelines for the treatment of candidemia (IDSA group); the remaining 99 (27.4%) patients received treatment different from the guidelines (non-IDSA group). Kaplan-Meier (KM) survival analysis for patients in the IDSA and non-IDSA group showed mortality rates of 21.9 and 13.6%, respectively; the difference between the two groups was not statistically significant (P = 0.093). Following the exclusion of patients requiring mechanical ventilation or acute cardiac support, the modified survival KM curves were similar between the two groups. Significantly more patients in the IDSA group required mechanical ventilation and tunneled central catheters, had a concomitant IFI, and received caspofungin. The duration of treatment and inappropriate dosing did not appear to have had a significant impact on survival. Most of the deviations from IDSA guidelines were due to the inappropriate duration and dosing of therapy. No significant difference in mortality was noted between the IDSA and non-IDSA groups. The basis of these differences merit further study.
Similar articles
-
Initial management of candidemia at an academic medical center: evaluation of the IDSA guidelines.Diagn Microbiol Infect Dis. 2005 May;52(1):29-34. doi: 10.1016/j.diagmicrobio.2004.12.010. Diagn Microbiol Infect Dis. 2005. PMID: 15878439
-
Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines.Pharmacoepidemiol Drug Saf. 2007 Aug;16(8):919-27. doi: 10.1002/pds.1365. Pharmacoepidemiol Drug Saf. 2007. PMID: 17286303
-
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.Clin Infect Dis. 2009 Jun 15;48(12):1695-703. doi: 10.1086/599039. Clin Infect Dis. 2009. PMID: 19441981
-
[Therapy of candidemia and invasive candidiasis according to guidelines].Mycoses. 2010 May;53 Suppl 1:30-5. doi: 10.1111/j.1439-0507.2009.01838.x. Mycoses. 2010. PMID: 20433654 Review. German.
-
[Echinocandins and the 2009 guidelines for treatment of candidiasis].Drugs Today (Barc). 2010 Mar;46 Suppl B:7-12. Drugs Today (Barc). 2010. PMID: 20407663 Review. Portuguese.
Cited by
-
Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Drug Healthc Patient Saf. 2010;2:27-38. doi: 10.2147/dhps.s6321. Epub 2010 Apr 20. Drug Healthc Patient Saf. 2010. PMID: 21701616 Free PMC article.
-
Treatment and outcomes of Candida osteomyelitis: review of 53 cases from the PATH Alliance® registry.Eur J Clin Microbiol Infect Dis. 2014 Jan;33(1):135-41. doi: 10.1007/s10096-013-1939-0. Epub 2013 Aug 2. Eur J Clin Microbiol Infect Dis. 2014. PMID: 23907587
-
Clinical characteristics and outcomes in 303 HIV-infected patients with invasive fungal infections: data from the Prospective Antifungal Therapy Alliance registry, a multicenter, observational study.HIV AIDS (Auckl). 2014 Mar 13;6:39-47. doi: 10.2147/HIV.S53910. eCollection 2014. HIV AIDS (Auckl). 2014. PMID: 24648769 Free PMC article.
-
Candidemia Treatment is Improved by Infectious Disease Consultation: A Population-Based Cohort Study.J Assoc Med Microbiol Infect Dis Can. 2024 Oct 25;9(3):129-139. doi: 10.3138/jammi-2024-0001. eCollection 2024 Oct. J Assoc Med Microbiol Infect Dis Can. 2024. PMID: 40556807 Free PMC article.
-
Candida parapsilosis, an emerging fungal pathogen.Clin Microbiol Rev. 2008 Oct;21(4):606-25. doi: 10.1128/CMR.00013-08. Clin Microbiol Rev. 2008. PMID: 18854483 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical